Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SLDB, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| SGT-003 | Duchenne Muscular Dystrophy | Phase 3 · NCT07160634 | Recruiting |
| SGT-212 | Friedreich's Ataxia (FA) | Phase 1 · NCT07180355 | Recruiting |
| SGT-501 | Catecholaminergic Polymorphic Ventricular Tachycardia | Phase 1 · NCT07148089 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SLDB holds $348.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $49.1M/quarter from operations, an estimated runway of 21.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 42 · Elevated
We believe that our cash, cash equivalents, and available-for-sale securities as of September 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SLDB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | Institution (13G, 5%+) | 12,046,579 | 10.79% | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. 10% owner |
Insider | 12,036,126 | 10.78% | 2026-11-04 |
| Raymond Debbane | 5%+ holder (13G) | 10,066,682 | 9.02% | 2026-03-31 |
| Bain Capital Life Sciences Investors, LL | Institution (13F) | 9,808,819 | 8.79% | 2026-09-30 |
| BCLS II Investco, LP | 5%+ holder (13D) | 8,604,852 | 7.71% | 2026-03-06 |
| Siren, L.L.C. | Institution (13F) | 7,690,405 | 6.89% | 2026-09-30 |
| FMR LLC | Institution (13G, 5%+) | 6,875,957 | 6.16% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 6,419,730 | 5.75% | 2026-06-30 |
| RTW Investments LP | Institution (13F) | 5,905,426 | 5.29% | 2026-09-30 |
| Armistice Capital, LLC | Institution (13F) | 4,496,000 | 4.03% | 2026-09-30 |
| Franklin Resources, Inc. | Institution (13F) | 4,193,497 | 3.76% | 2026-09-30 |
| Franklin Templeton, Inc. | Institution (13F) | 4,193,497 | 3.76% | 2026-09-30 |
Share count 111,610,531 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-01 filed 2026-10-26 |
Ganot Ilan |
Option award (A) | 150,000 | – | – |
| 2026-10-19 filed 2026-10-20 |
Brooks Gabriel |
Sale (S) | 4,374 | $5.62 | 97,241 |
| 2026-10-18 filed 2026-10-20 |
Brooks Gabriel |
Option exercise (M) | 9,750 | – | 101,615 |
| 2026-10-18 filed 2026-10-20 |
Brooks Gabriel |
Option exercise (M) | 9,750 | – | – |
| 2026-10-02 filed 2026-10-06 |
SMITH IAN F |
Option exercise (M) | 3,440 | – | 141,585 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLDB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →